Tabassum H Laz1, Mahbubur Rahman, Abbey B Berenson. 1. Center for Interdisciplinary Research in Women's Health, Department of Obstetrics & Gynecology, University of Texas Medical Branch, Galveston, TX 77555-0587, USA.
Abstract
PURPOSE: A 3-dose human papillomavirus (HPV) vaccine is recommended for adolescents to protect against HPV-related cervical and other cancers. The purpose of this study was to provide an update on HPV vaccine uptake among 11-17 year old girls residing in the US. METHODS: Data from the 2010 National Health Interview Survey (NHIS) were obtained to assess HPV vaccination status and its correlates. Multivariate logistic regression analyses were performed to examine HPV vaccine uptake of ≥ 1 dose and ≥ 3 doses among all girls, and completion of the 3-dose series among those who initiated (received ≥ 1 dose) the vaccine. RESULTS: Overall, 28.9% and 14.2% received ≥ 1 dose and ≥ 3 doses of vaccine: 14.5% and 3.0% among 11-12 year old girls, and 34.8% and 18.7% among 13-17 year olds, respectively. Hispanics had higher uptake of ≥ 1 dose (odds ratio (OR) 1.63, 95% confidence interval (CI) 1.22-2.17) than whites. Having received an influenza shot in the past year and parents' awareness of the vaccine were significantly associated with receiving ≥ 1 dose (OR 1.88, 95% CI 1.51-2.33 and OR 16.57, 95% CI 10.95-25.06) and ≥ 3 doses (OR 1.48, 95% CI 1.13-1.92 and OR 10.60, 95% CI 5.95-18.88). A separate multivariate model based on girls who initiated the vaccine did not identify any significant correlates of 3-dose series completion. Among parents of unvaccinated girls, 60% were not interested in vaccinating their daughters and mentioned three main reasons: "does not need vaccine" (25.5%), "worried about safety" (19.3%) and "does not know enough about vaccine" (16.6%). Of those who were interested, 53.7% would pay $360-$500 for the vaccination, while 41.7% preferred to receive it at a much lower cost or free. CONCLUSIONS: Only 1 out of 3 girls (11-17 years) have received ≥ 1 dose of HPV vaccine and much less have completed all 3 doses. Strategies should be taken to improve this vaccine uptake among girls, especially those 11-12 year olds, and to educate parents about the importance of vaccination.
PURPOSE: A 3-dose human papillomavirus (HPV) vaccine is recommended for adolescents to protect against HPV-related cervical and other cancers. The purpose of this study was to provide an update on HPV vaccine uptake among 11-17 year old girls residing in the US. METHODS: Data from the 2010 National Health Interview Survey (NHIS) were obtained to assess HPV vaccination status and its correlates. Multivariate logistic regression analyses were performed to examine HPV vaccine uptake of ≥ 1 dose and ≥ 3 doses among all girls, and completion of the 3-dose series among those who initiated (received ≥ 1 dose) the vaccine. RESULTS: Overall, 28.9% and 14.2% received ≥ 1 dose and ≥ 3 doses of vaccine: 14.5% and 3.0% among 11-12 year old girls, and 34.8% and 18.7% among 13-17 year olds, respectively. Hispanics had higher uptake of ≥ 1 dose (odds ratio (OR) 1.63, 95% confidence interval (CI) 1.22-2.17) than whites. Having received an influenza shot in the past year and parents' awareness of the vaccine were significantly associated with receiving ≥ 1 dose (OR 1.88, 95% CI 1.51-2.33 and OR 16.57, 95% CI 10.95-25.06) and ≥ 3 doses (OR 1.48, 95% CI 1.13-1.92 and OR 10.60, 95% CI 5.95-18.88). A separate multivariate model based on girls who initiated the vaccine did not identify any significant correlates of 3-dose series completion. Among parents of unvaccinated girls, 60% were not interested in vaccinating their daughters and mentioned three main reasons: "does not need vaccine" (25.5%), "worried about safety" (19.3%) and "does not know enough about vaccine" (16.6%). Of those who were interested, 53.7% would pay $360-$500 for the vaccination, while 41.7% preferred to receive it at a much lower cost or free. CONCLUSIONS: Only 1 out of 3 girls (11-17 years) have received ≥ 1 dose of HPV vaccine and much less have completed all 3 doses. Strategies should be taken to improve this vaccine uptake among girls, especially those 11-12 year olds, and to educate parents about the importance of vaccination.
Authors: Jessica A Kahn; Lili Ding; Bin Huang; Gregory D Zimet; Susan L Rosenthal; A Lindsay Frazier Journal: Pediatrics Date: 2009-06 Impact factor: 7.124
Authors: Lauri E Markowitz; Eileen F Dunne; Mona Saraiya; Herschel W Lawson; Harrell Chesson; Elizabeth R Unger Journal: MMWR Recomm Rep Date: 2007-03-23
Authors: Meg Watson; Mona Saraiya; Vicki Benard; Steven S Coughlin; Lisa Flowers; Vilma Cokkinides; Molly Schwenn; Youjie Huang; Anna Giuliano Journal: Cancer Date: 2008-11-15 Impact factor: 6.860
Authors: Jessica A Kahn; Susan L Rosenthal; Yan Jin; Bin Huang; Azadeh Namakydoust; Gregory D Zimet Journal: Obstet Gynecol Date: 2008-05 Impact factor: 7.661
Authors: Susan L Rosenthal; Richard Rupp; Gregory D Zimet; Heather M Meza; Melissa L Loza; Mary B Short; Paul A Succop Journal: J Adolesc Health Date: 2008-09 Impact factor: 5.012
Authors: Suzanne M Garland; Marc Steben; Heather L Sings; Margaret James; Shuang Lu; Radha Railkar; Eliav Barr; Richard M Haupt; Elmar A Joura Journal: J Infect Dis Date: 2009-03-15 Impact factor: 5.226
Authors: L L Villa; R L R Costa; C A Petta; R P Andrade; J Paavonen; O-E Iversen; S-E Olsson; J Høye; M Steinwall; G Riis-Johannessen; A Andersson-Ellstrom; K Elfgren; G von Krogh; M Lehtinen; C Malm; G M Tamms; K Giacoletti; L Lupinacci; R Railkar; F J Taddeo; J Bryan; M T Esser; H L Sings; A J Saah; E Barr Journal: Br J Cancer Date: 2006-11-21 Impact factor: 7.640
Authors: Ping Du; Fabian Camacho; Jennifer McCall-Hosenfeld; Eugene Lengerich; Craig M Meyers; Neil D Christensen Journal: J Public Health Manag Pract Date: 2015 Nov-Dec
Authors: Abbey B Berenson; Eneida Male; Toy G Lee; Alan Barrett; Kwabena O Sarpong; Richard E Rupp; Mahbubur Rahman Journal: Am J Obstet Gynecol Date: 2013-11-23 Impact factor: 8.661
Authors: Kristen A Feemster; Maria Middleton; Alexander G Fiks; Sarah Winters; Sara B Kinsman; Jessica A Kahn Journal: Hum Vaccin Immunother Date: 2014-10-30 Impact factor: 3.452